A Comparison of Completeness and Complication of Total Thyroidectomy with or Without Neuromonitoring

Objectives

Total Thyroidectomy (TT) in true sense is not total as evidenced by remnant uptake in radio-iodine scans and serum thyroglobulin. The aim of this study is to assess the completeness of TT, operating time and recurrent laryngeal nerve injury with and without neuro-monitoring (IONM).

Methods

Cross sectional analytical study using retrospective data of patients undergoing total thyroidectomy for benign and malignant goiters. Surgeries performed by single surgeon. Patients undergoing TT (2015-22) were grouped into Group A (n = 400) and Group B (n = 400) based on use of IONM. Subgroup of patients (Group A1&B1) who had differentiated thyroid cancer were compared for completeness of thyroidectomy with DxWBS and serum thyroglobulin (TG). Group A and B were compared for operating time and incidence of RLN palsy.

Results

Of the 800 RLN at risk transient RLN palsy was lower with IONM (p = 0.048). Mean operating time was significantly higher in Group-B(p = 0.0038). Subgroup A1 showed lower radio-active iodine uptake percentage, higher number of patients with negative scan, TG of < 1ng/mL indicating better completeness of TT.

Conclusion

Our study shows better completeness of thyroidectomy, lower incidence of transient RLN palsy and shorter operating time with IONM.

Epidemiology, management and outcomes of Graves' disease-real life data

PURPOSE

Treatment options in Graves' disease are clearly defined, but management practices and the perceptions of success are varied. The outcomes of treatment in large consecutive cohorts of Graves' disease have not been well characterised. The study describes the epidemiology, management strategies and medium term outcomes following anti-thyroid drug treatment, radio-iodine ablation and surgery in Graves' disease.

METHODS

All patients (n = 659) who received treatment for a new diagnosis of Graves' disease in secondary care over a 5 year period were included with a median (interquartile range) follow-up of 42.9 (29-57.5) months.

RESULTS

The age adjusted incidence of adult onset Graves' disease in Sheffield, UK was 24.8 per 100,000 per year. Excluding 35 patients lost to follow-up, 93.1% (n = 581) were controlled on anti-thyroid drug treatment. Of these, 73.6% went into remission following withdrawal of anti-thyroid drugs; 5.2% were still undergoing initial therapy; 13.3% lost control whilst on anti-thyroid drugs; and 7.9% went on to have either surgery or radio-iodine ablation whilst controlled on anti-thyroid drugs. Of the 428 patients who achieved remission, 36.7% relapsed. Of 144 patients who had radio-iodine ablation treatment, 5.6% relapsed and needed further treatment. Of 119 patients having surgery, 5.2% had long-term hypoparathyroidism and none had documented long-term recurrent laryngeal nerve palsy.

CONCLUSIONS

In the follow-up, 39.9% of patients underwent surgery or radio-iodine ablation with little morbidity. Up to two-thirds of patients who achieved remission did not relapse. Data on effectiveness and risks of treatments for Graves' disease presented in this study will help clinicians and patients in decision making.

Statistical and radiobiological analysis of the so-called thyroid stunning

Background

The origin of the reduction in thyroid uptake after a low activity iodine scan, so-called stunning effect, is still controversial. Two explanations prevail: an individual cell stunning that reduces its capability to store iodine without altering its viability, and/or a significant cell-killing fraction that reduces the number of cells in the tissue still taking up iodine. Our aim is to analyze whether this last assumption could explain the observed reduction.

Methods

The survival fraction after administration of a small radioiodine activity was computed by two independent methods: the application of the statistical theory underlying tissue control probability on recent clinical studies of thyroid remnant ¹³¹I ablation and the use of the radiosensitivities reported in human thyroid cell assays for different radioiodine isotopes.

Results

Both methods provided survival fractions in line with the uptake reduction observed after a low ¹³¹I activity scan. The second method also predicts a similar behavior after a low ¹²³I or ¹²⁴I activity scan.

Conclusions

This study shows that the cell-killing fraction is sufficient to explain the uptake reduction effect for ¹³¹I and ¹²³I after a low activity scan and that even if some still living cells express a stunning effect just after irradiation (as shown in vitro), they will mostly die with time. As the β/α value is very low, this therapy fractionation should not impact the patient outcome in agreement with recent studies. However, in case of huge uptake heterogeneity, pre-therapy scan could specifically kills high-uptake cells and by the way could reduce the cross irradiation to the low-uptake cells during the therapy, resulting in a reduction of the ablation success rate.

Electronic supplementary material

The online version of this article (doi:10.1186/s13550-015-0144-9) contains supplementary material, which is available to authorized users.